BUZZ-Oncolytics Biotech Inc: Orphan drug status for drug

Fri Apr 17, 2015 7:59am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian cancer drug developer's U.S.-listed shares up 14 pct at 79 cents premarket

** Says its experimental drug Reolysin gets orphan drug status from U.S. FDA

** Drug being developed for treating malignant glioma, a type of tumor that affects the brain and spine

** Orphan status, granted to drugs developed to treat rare diseases, gives developer several incentives including seven-year marketing exclusivity in U.S.

** Up to Thursday's close, stock had fallen 54 pct in the past 12 months